272 related articles for article (PubMed ID: 18834412)
1. Tumor dormancy and immunoescape.
Quesnel B
APMIS; 2008; 116(7-8):685-94. PubMed ID: 18834412
[TBL] [Abstract][Full Text] [Related]
2. Dormant tumor cells as a therapeutic target?
Quesnel B
Cancer Lett; 2008 Aug; 267(1):10-7. PubMed ID: 18384938
[TBL] [Abstract][Full Text] [Related]
3. Tumor dormancy: long-term survival in a hostile environment.
Quesnel B
Adv Exp Med Biol; 2013; 734():181-200. PubMed ID: 23143980
[TBL] [Abstract][Full Text] [Related]
4. Tumor dormancy of primary and secondary cancers.
Udagawa T
APMIS; 2008; 116(7-8):615-28. PubMed ID: 18834406
[TBL] [Abstract][Full Text] [Related]
5. Immune-mediated dormancy: an equilibrium with cancer.
Teng MW; Swann JB; Koebel CM; Schreiber RD; Smyth MJ
J Leukoc Biol; 2008 Oct; 84(4):988-93. PubMed ID: 18515327
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell dormancy: implications for the biology and treatment of breast cancer.
Fehm T; Mueller V; Marches R; Klein G; Gueckel B; Neubauer H; Solomayer E; Becker S
APMIS; 2008; 116(7-8):742-53. PubMed ID: 18834416
[TBL] [Abstract][Full Text] [Related]
7. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
Salih HR; Nüssler V
Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms underlying tumor dormancy.
Almog N
Cancer Lett; 2010 Aug; 294(2):139-46. PubMed ID: 20363069
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?
Quesnel B
Expert Rev Vaccines; 2006 Dec; 5(6):773-81. PubMed ID: 17184216
[TBL] [Abstract][Full Text] [Related]
10. [Tumor dormancy and identification of therapeutic targets].
Li CF; Cao S; Meng SD
Ai Zheng; 2009 May; 28(5):555-8. PubMed ID: 19624889
[TBL] [Abstract][Full Text] [Related]
11. New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?
Goss P; Allan AL; Rodenhiser DI; Foster PJ; Chambers AF
APMIS; 2008; 116(7-8):552-68. PubMed ID: 18834402
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted kinetics of immuno-evasion from tumor dormancy.
d'Onofrio A
Adv Exp Med Biol; 2013; 734():111-43. PubMed ID: 23143978
[TBL] [Abstract][Full Text] [Related]
13. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer.
Romero I; Garrido F; Garcia-Lora AM
Cancer Res; 2014 Dec; 74(23):6750-7. PubMed ID: 25411345
[TBL] [Abstract][Full Text] [Related]
14. Adaptive immunity maintains occult cancer in an equilibrium state.
Koebel CM; Vermi W; Swann JB; Zerafa N; Rodig SJ; Old LJ; Smyth MJ; Schreiber RD
Nature; 2007 Dec; 450(7171):903-7. PubMed ID: 18026089
[TBL] [Abstract][Full Text] [Related]
15. New dimensions in tumor immunology: what does 3D culture reveal?
Feder-Mengus C; Ghosh S; Reschner A; Martin I; Spagnoli GC
Trends Mol Med; 2008 Aug; 14(8):333-40. PubMed ID: 18614399
[TBL] [Abstract][Full Text] [Related]
16. Tumor stress, cell death and the ensuing immune response.
Ullrich E; Bonmort M; Mignot G; Kroemer G; Zitvogel L
Cell Death Differ; 2008 Jan; 15(1):21-8. PubMed ID: 17992190
[TBL] [Abstract][Full Text] [Related]
17. Spatiotemporal effects of a possible chemorepulsion of tumor cells by immune system effectors.
d'Onofrio A
J Theor Biol; 2012 Mar; 296():41-8. PubMed ID: 22119911
[TBL] [Abstract][Full Text] [Related]
18. Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy.
Favaro E; Amadori A; Indraccolo S
APMIS; 2008; 116(7-8):648-59. PubMed ID: 18834409
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment and immune escape.
Ferrone S; Whiteside TL
Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
[TBL] [Abstract][Full Text] [Related]
20. Cancer micrometastasis and tumour dormancy.
Wikman H; Vessella R; Pantel K
APMIS; 2008; 116(7-8):754-70. PubMed ID: 18834417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
